POXEL news, videos and press releases - Page 2
For more news please use our advanced search feature.
POXEL - More news...
POXEL - More news...
- Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
- Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
- Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
- Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting
- Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
- Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
- Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
- Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
- Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022
- Poxel Announces Availability of Its 2021 Universal Registration Document
- Poxel Announces Its Participation in Upcoming Scientific Conferences
- Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
- Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update
- Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022
- Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy
- Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update
- Poxel Announces Financial Calendar for 2022
- Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
- Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
- Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021
- Poxel Announces its Participation at Investor Conferences in October 2021
- Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD)
- Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update
- Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients
- Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021
- Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes
- Poxel Announces Its Participation at Investor and Scientific Conferences in September
- Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston